The tantalum monohydride compound [Ta(OC 6 H 3 Pr i 2 -2,6) 2 Cl 2 (H)(PMe 2 Ph) 2 ] ( 1 ) reacts with organic isocyanides RNC to produce the phosphine adduct η 2 -iminoformyl complexes [Ta(OC 6 H 3 Pr i 2 -2,6) 2 Cl 2 {HC(PMe 2 Ph)NR}] (R = 2,6-diisopropylphenyl ( 2a ), 2,6-dimethylphenyl ( 2b ), tert -butyl ( 2c )). Compounds 2b, c were only detected spectroscopically as intermediates, while 2a was isolated and reacted with PMe 3 to produce the complex [Ta(OC 6 H 3 Pr i 2 -2,6) 2 Cl 2 {HC(PMe 3 )NC 6 H 3 Pr i 2 -2,6}] ( 3 ), which was structurally characterized. The structure of 3 is best described as trigonal bipyramidal about tantalum with a chloride atom and the phosphine adduct of an η 2 -iminoformyl group occupying axial sites. Important structural parameters for 3 are Ta−N = 1.956(4), Ta−C = 2.210(5), and N−C = 1.421(7) Å. Compounds 2a and 3 do not react with a further 1 equiv of 2,6-diisopropylphenyl isocyanide. In contrast 2b reacts with 2,6-dimethylphenyl isocyanide to produce the ylide derivative [Ta(OC 6 H 3 Pr i 2 -2,6) 3 Cl 2 {RN CHC( PMe 2 Ph)NR}] ( 4 ) (R = C 6 H 3 Me 2 -2,6), while 2c reacts with an additional 2 equiv of Bu t NC to produce the compound [Ta(OC 6 H 3 Pr i 2 -2,6) 3 Cl 2 {Bu t N CHC( C NBu t )NBu t }] ( 5 ). Spectroscopic data on 4 and 5 and a single-crystal X-ray diffraction study of 5 show both molecules contain 2,5-diazacyclopent-2-ene rings with either ylide ( 4 ) or keteneimine ( 5 ) groups attached to the C-4 position. Addition of Bu t NC to 2a produces the complex [Ta(OC 6 H 3 Pr i 2 -2,6) 2 Cl 2 {RN CHC( C NBu t )NBu t }] ( 6 ) (R = C 6 H 3 Pr i 2 -2,6). The tantalum dihydride compound [Ta(OC 6 H 3 Bu t 2 -2,6) 2 Cl 2 (H)(PMePh 2 )] ( 7 ) reacts with RNC to produce the monocyclometalated derivatives [Ta(OC 6 H 3 Bu t -CMe 2 CH 2 )(OC 6 H 3 Bu t 2 -2,6)Cl 2 {N(R)CH 3 }] ( 8 ) ( a, R = C 6 H 3 Me 2 -2,6; b, R = Bu t ), in which a total of three hydride groups have been transferred to the isocyanide substrate to produce the dialkylamido ligand.
No takes yet. Share an insight, caveat, or question.
Clark et al. (1996) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: